Azienda Socio Sanitaria Territoriale Della Valle Olona
- Address
- Via Arnaldo Da Brescia 1, 21052 Saronno, Italy
Nervous System Diseases and Traumatic Brain Injury Research
At Azienda Socio Sanitaria Territoriale Della Valle Olona in Saronno, the Neuroscience department is involved in clinical research focused on nervous system diseases, with a strong emphasis on subacute moderate to severe traumatic brain injury. These studies are designed to assess the safety and tolerability of a new treatment approach and to explore its potential to support recovery in adults with brain injury.
- Study of traumatic brain injury care in adults with moderate to severe injury
- Evaluation of a new intranasal therapy for safety, tolerability, and possible clinical benefit
- Research aimed at improving treatment options in neurorehabilitation
This work reflects a small but focused effort to advance neurologic care through early clinical testing and better understanding of treatment effects.
Nutritional and Metabolic Diseases in Chronic Dialysis Care
The site is also conducting research in nutritional and metabolic diseases, centered on end stage kidney disease in people receiving chronic dialysis therapy. The trial is examining whether a potassium-binding treatment can help patients reduce strict dietary potassium limits without increasing the risk of hyperkalemia, while also looking at quality of life and nutrition.
- End stage kidney disease in patients on chronic dialysis
- Assessment of a treatment intended to support safer potassium control
- Interest in improving dietary flexibility, nutrition, and patient well-being
At this hospital/clinic, the research combines kidney care and nutrition-focused outcomes to better understand how treatment may improve everyday management for dialysis patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1AstraZeneca AB2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Socio Sanitaria Territoriale Della Valle Olona
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO). | AstraZeneca AB | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 2 | Unknown | 2020-10-23 | 2022-06-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.